Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Published:2020-12 Issue:12 Volume:19 Page:998-1009
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Wolinsky Jerry S,Arnold Douglas L,Brochet Bruno,Hartung Hans-Peter,Montalban Xavier,Naismith Robert T,Manfrini Marianna,Overell James,Koendgen Harold,Sauter Annette,Bennett Iain,Hubeaux Stanislas,Kappos Ludwig,Hauser Stephen L

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference36 articles.

1. Ocrelizumab versus placebo in primary progressive multiple sclerosis;Montalban;N Engl J Med,2017

2. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis;Wilson;Int J MS Care,2015

3. New insights into the burden and costs of multiple sclerosis in Europe;Kobelt;Mult Scler,2017

4. Contribution of impaired mobility to patient burden in multiple sclerosis;Sutliff;Curr Med Res Opin,2010

5. Physical disability, anxiety and depression in people with MS: an internet-based survey via the UK MS register;Jones;PLoS One,2014

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression;International Journal of Molecular Sciences;2024-08-11

2. The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-08

3. New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis;Frontiers in Cellular Neuroscience;2024-08-05

4. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

5. Integrated elemental analysis supports targeting copper perturbations as a therapeutic strategy in multiple sclerosis;Neurotherapeutics;2024-08